Ablynx and Spirogen Enter Into a Research Collaboration
News Sep 16, 2013
Ablynx and Spirogen Ltd. have announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.
Under the terms of the collaboration, Ablynx will provide access to novel Nanobodies against a specific, undisclosed cancer target and Spirogen will provide access to its proprietary cytotoxic warheads (PBDs) and conjugation technologies.
Both companies will contribute their resources towards the collaboration, which is expected to last for up to a year initially.
Following this feasibility phase, Ablynx will have the option to either in-license Spirogen’s technology or, in collaboration with Spirogen, move development forward with a third party. No further terms have been disclosed.
Dr Andreas Menrad, Chief Scientific Officer of Ablynx, said: “We are very pleased to be working with Spirogen to discover and develop novel cancer therapeutics based on both companies’ proprietary technologies. Our Nanobodies have the potential to selectively and efficiently deliver Spirogen’s PBD drugs to the site of the tumour. We are very excited about combining our unique and powerful technology with Spirogen’s novel cytotoxic agents to search for breakthrough opportunities in oncology.”
Dr Chris Martin, Chief Executive Officer of Spirogen, said: “The collaboration with Ablynx is designed to evaluate the potential of a Nanobody to act as the targeting molecule for the PBD warhead, which is released once it is inside the cancer cell. These warheads have the potential to be extremely potent without distorting the DNA helix thus avoiding mechanisms that lead to tumours becoming resistant to other anti-cancer drugs.”
Why Might Super-Tasters be at Higher Cancer Risk?News
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been tracked for about 20 years.READ MORE
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
Study in Mouse Model of Autism Finds Mother's Microbiome Determines RiskNews
The microbiome is the collection of microorganisms, such as bacteria, that naturally live inside us. New research in a mouse model suggests the microbiome determines autism risk.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018